Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients
Authors:
- 1 August 1996
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 15 (8) , 625-634
Abstract
The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients. Patients were assigned to either imipenem 500 mg/m2 (500 mg for bone marrow transplant recipients) every 6 h or cefoperazone (2 g)-sulbactam (1 g) every 8 h. All patients received vancomycin 1 g every 12 h. A total of 457 febrile or infectious episodes occurring in 407 patients were entered in the study. The response rate was 73% for imipenem plus vancomycin and 74% for cefoperazone-sulbactam plus vancomycin among the 369 episodes that could be evaluated. Response rates were comparable for the two regimens with regard to infecting organism, administration of antimicrobial prophylaxis, and neutrophil count and trend. The frequency of side-effects was significantly higher for imipenem plus vancomycin (11 % vs. 5%, p = 0.02), due to therapy-associated nausea and vomiting (5.3% vs. 0%, p = 0.0004). The overall frequency of superinfections was similar with both regimens, butClostridium difficile colitis occurred significantly more often in patients receiving imipenem plus vancomycin (5 vs. 0, p = 0.02). In this study cefoperazone-sulbactam plus vancomycin was an effective alternative to imipenem plus vancomycin for initial therapy of fever in neutropenic patients.Keywords
This publication has 36 references indexed in Scilit:
- The Changing Epidemiology of Infections at Cancer HospitalsClinical Infectious Diseases, 1993
- Septicemia and Shock Syndrome Due to Viridans Streptococci: A Case-Control Study of Predisposing FactorsClinical Infectious Diseases, 1992
- A randomized clinical study of cefoperazone and sulbactam versus gentamicin and clindamycin in the treatment of infra-abdominal infectionsJournal of Antimicrobial Chemotherapy, 1990
- In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patientsDiagnostic Microbiology and Infectious Disease, 1989
- Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseasesDiagnostic Microbiology and Infectious Disease, 1989
- Effect of a Single Dose of Cefotaxime or Ceftriaxone on Human Faecal FloraDrugs, 1988
- Imipenem/cilastatin therapy of infections in cancer patientsCancer, 1987
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986
- A Randomized Comparative Trial of Three Aminoglycosides—Comparison of Continuous Infusions of Gentamicin, Aaikacin and Sisomicin Combined with Carbenicillin in the Treatment of Infections in Neutropenic Patients with MalignanciesMedicine, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958